SWISS MEDICAL NETWORK



Dr. med. Michael Montemurro

FMH Specialist in Hematology
FMH Specialist in Internal Medicine
Specialist in Internal Medicine, Hematology and Medical Oncology

Languages

EN,DE,FR,IT

Work Experience

since 2021	Consultant, Medical Oncology - University College London Hospitals, UK
2020	Chief Physician, Medical Oncology – EHC Morges Hospital, CH
2016–2020	Deputy Physician, Medical Oncology - CHUV Lausanne, CH
2014–2015	Associate Physician, Medical Oncology - IOSI-EOC, Ospedale Bellinzona, CH
2013–2014	Sarcoma Unit, The Royal Marsden Hospital London, UK
2012	Medical oncology, CHU Zurich, CH
2005–2012	Multidisciplinary Oncology Center (CePO), CHUV Lausanne, CH

Education

2019	ESMO Exam Medical Oncology
2003	Internal hematology and oncology
2002	Internal Medicine
1999	Research thesis, Faculty of Medicine, Essen University, Germany
1989–1995	Medical studies, Johann Wolfgang Goethe Universität, Frankfurt, Germany

Competences

- Digestive tumors: colon, rectum, liver, pancreas, stomach, esophagus, neuro-endocrine
- GIST (gastrointestinal stromal tumor)
- Soft tissue and bone sarcomas

Memberships

- 2009 – 2020: ESMO Faculty Member GIST / Sarcoma (ESMO Guidelines Sarcoma, GIST)
- 2011 – 2016: President of SAKK project group "Gastrointestinal Cancer"
- 2010: Founding member of “Groupe GIST Suisse”

Publications

Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Montemurro M, 2021 Feb;27(2):289-300

Prediction of tumor grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma. Dunet V, Halkic N, Sempoux C, Demartines N, Montemurro M, Prior JO, Schmidt S.; Eur Radiol. 2021 Feb;31(2):992-1001

LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma
Montemurro, M., et al. Cell Rep. 2020 Mar 31;30(13):4567-4583

Oncological outcome, functional results and costs after unplanned excision of musculoskeletal soft tissue sarcoma
Morattel , Mustaki, Montemurro, Letovanec, Durham, Becce, Omoumi, di Summa, Matter, Ru□diger , Cherix Eur J Surg Oncol. 2020 May;46(5):898-904

Tumor response and outcome after reverse treatment for patients with synchronous colorectal liver metastasis ....
Du Pasquier C, Roulin D, Bize P, Sempoux C, Rebecchini C, Montemurro M, Scha□fer M, Halkic N, Demartines N. BMC Surg. 2020 Apr 19;20(1):78

Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer...
De Bari B, Franzetti-Pellanda A, Saidi A, Biggiogero M, Hahnloser D, Montemurro M, Bourhis J, Zeverino M, Ozsahin M. J Cancer Res Clin Oncol. 2019 Apr;145(4):1075-1084

Long-term outcome of dasatinib first-line treatment in GIST: A multicenter, 2-stage phase 2 trial (SAKK 56/07).
Montemurro M et al.; Cancer. 2018 Apr 1;124(7):1449-1454

Sarcoma of the heart: survival after surgery.
Niclauss L, Montemurro M, Kirsch M, Pre□tre R.; Interact Cardiovasc Thorac Surg. 2018 Aug; 27(2):198-201

Radiation Therapy for GIST Progressing During Or After Tyrosine Kinase Inhibitor Therapy: A Prospective Study
Joensuu H, Eriksson M, Collan J, Balk M, Leyvraz S, Montemurro M; Radiother Oncol. 2015 Aug; 116(2):233-8

Survival after surgical drainage of malignant pericardial effusion Niclauss L, Montemurro M, Pre□tre R; World J Surg 2015 Jul;39(7):1767

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour .....
M. Montemurro et al.; European Journal of Cancer 2013 Mar;49(5):1027-31

Continuous Sunitinib treatment in patients with advanced HCC: a SAKK and SASL multicenter phase II trial (SAKK 77/06). Koeberle D, Montemurro M et al.; Oncologist. 2010;15(3):285-92.

Early prediction of response to sunitinib after imatinib failure by 18F-FDG-PET in patients with GIST
Prior JO, Montemurro M et al.; J Clin Oncol. 2009 Jan 20;27(3):439-45. Epub 2008 Dec 8. Nilotinib in the treatment of advanced gastrointestinal stromal tumors resistant to both imatinib and sunitinib. Montemurro M et al.; Eur J Cancer. 2009 Sep;45(13):2293-7

PCNSL treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell
transplantation and response-adapted whole-brain radiotherapy: results of the multicenter OSHO-53 phase II study. Montemurro M et al.; Ann Oncol. 2007 Apr;18(4):665-71.

Book chapter
Principles of Tumor Therapy
In: “HEROLD – INNERE MEDIZIN”, Gerd Herold (editor), Germany; since 2010, annual update

Awards

- 2018 : Annual prize of GIST Group / Swiss Group
- 2012 : Annual prize of GIST Group / Swiss Group
- 2011 : Honorary Prize of the GIST Group Switzerland for "Living with GIST"

- 2011 : Edi 2011 (silver): Film documentary: "Living with GIST"
- 2011 : Honorary member of GIST Group Switzerland (www.gist.ch)
- 2010 : Annual prize of GIST Group / Swiss Group

Accreditation

Clinique de Genolier

Clinique de Montchoisi

Specialties

Hematology

General Internal Medicine

Oncology

Onco-haematology

Contact

Clinique de Genolier
Route du Muids 3
1272 Genolier

T T +41 22 366 90 72
fmansouri@genolier.net

Download vCard